These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20224591)

  • 1. Sudden cardiac death and mineral metabolism in chronic kidney disease.
    Afsar B; Elsurer R
    Kidney Int; 2010 Apr; 77(7):648; author reply 648-9. PubMed ID: 20224591
    [No Abstract]   [Full Text] [Related]  

  • 2. PTH, FGF-23 and early CKD.
    Rodriguez M; Felsenfeld AJ
    Nephrol Dial Transplant; 2008 Nov; 23(11):3391-3. PubMed ID: 18676347
    [No Abstract]   [Full Text] [Related]  

  • 3. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
    Akiba T
    Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogenesis and treatment of vascular calcification in CKD].
    Brancaccio D; Gallieni M; Pasho S; Fallabrino G; Olivi L; Volpi E; Ciceri P; Missaglia E; Ronga C; Brambilla C; Butti A; Rocca-Rey L; Chiarelli G; Cozzolino M
    G Ital Nefrol; 2009; 26 Suppl 45():S20-7. PubMed ID: 19382090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?
    Gal-Moscovici A; Sprague SM; Hutchison AJ; Shah N; Piraino B; Cunningham J
    Semin Dial; 2007; 20(1):24-32. PubMed ID: 17244115
    [No Abstract]   [Full Text] [Related]  

  • 6. [Correlations between the levels of vitamin D, parathormone, calcium, blood phosphates in patients with chronic kidney disease not treated with kidney replacement therapy].
    Smirnov AV; Volkov MM; Galkina OV; Zhloba AA; Emanuél' VL
    Ter Arkh; 2009; 81(8):49-52. PubMed ID: 19799200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taking aim at targets.
    Palmer SC; Craig JC; Strippoli GF
    Nephrol Dial Transplant; 2009 May; 24(5):1358-61. PubMed ID: 19211650
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effects of dialysis with cuprophan versus polyacrylonitrile membranes on plasma immunoreactive parathyroid hormone levels in patients on chronic hemodialysis.
    Gueris J; Fournier A; Sebert JL; De Fremont JF; Ferriere C; Covoet B; Quichaud J
    Calcif Tissue Res; 1977 May; 22 Suppl():434-8. PubMed ID: 912564
    [No Abstract]   [Full Text] [Related]  

  • 9. Failure to show a correlation between serum parathyroid hormone, nerve conduction velocity and serum lipids in hemodialysis patients.
    Schaefer K; Offermann G; von Herrath D; Schröter R; Stölzel R; Arntz HR
    Clin Nephrol; 1980 Aug; 14(2):81-8. PubMed ID: 7408260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of serum ionized calcium and immunoreactive parathyroid hormone in patients with renal disorders].
    Chen HJ; Lai YH; Su YH; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1985 Mar; 1(3):188-94. PubMed ID: 3871031
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T; Yamamoto H
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone.
    Elder G; Faull R; Branley P; Hawley C;
    Nephrology (Carlton); 2006 Apr; 11 Suppl 1():S230-61. PubMed ID: 16684078
    [No Abstract]   [Full Text] [Related]  

  • 14. Failure to detect an effect of bilateral nephrectomy (NPX) upon parathyroid hormone (PTH) levels in azotemic human subjects.
    Hattner RS; Johnson JW; Bernstein DS; Hampers CL
    J Clin Endocrinol Metab; 1970 May; 30(5):677-9. PubMed ID: 5444557
    [No Abstract]   [Full Text] [Related]  

  • 15. [Phosphorus and calcium metabolism and the cardiovascular system status in patients with early-stage chronic renal disease].
    Smirnov AV; Volkov MM; Dobronravov VA; Rafrafi H
    Ter Arkh; 2010; 82(6):25-8. PubMed ID: 20731105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study on dialysis patients after total parathyroidectomy without autoimplant.
    Chan HW; Chu KH; Fung SK; Tang HL; Lee W; Cheuk A; Yim KF; Tong MK; Lee KC
    Nephrology (Carlton); 2010 Jun; 15(4):441-7. PubMed ID: 20609096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parathormone and calcitonin in the blood in chronic kidney diseases].
    Mosin VM; Iagoda AV; Salanda BS; Derevianko NA
    Ter Arkh; 1982; 54(7):82-4. PubMed ID: 7135230
    [No Abstract]   [Full Text] [Related]  

  • 18. Mineral metabolism and mortality in patients with chronic kidney disease.
    Young EW
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):13-21. PubMed ID: 17200039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sudden cardiac death from the perspective of coronary artery disease.
    Sara JD; Eleid MF; Gulati R; Holmes DR
    Mayo Clin Proc; 2014 Dec; 89(12):1685-98. PubMed ID: 25440727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?
    Deger SM; Mutluay R; Derici U; Mandiralioglu F; Arinsoy T; Sindel S
    Med Princ Pract; 2011; 20(1):85-9. PubMed ID: 21160221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.